Reactifargan

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Reactifargan

Property Description
Active ingredient Promethazine
Form Cream or Emulsion (Topical)
Pharmacological class First-generation H1 Antihistamine
General purpose Local relief of itching and burning
Origin Synthetic, Phenothiazine derivative

Reactifargan is a specialized topical pharmaceutical preparation intended for localized application to the skin, with its chemical identity defined by the active substance, Promethazine.

What Type of Medicine is Reactifargan?

Reactifargan is classified as a first-generation H1 Antihistamine, a therapeutic designation that confirms its primary action involves blocking the effects of histamine. The active ingredient, Promethazine, is further identified as a phenothiazine derivative, a class of synthetic compounds. While the chemical substance Promethazine is also utilized in systemic forms for generalized conditions like systemic allergies, nausea, and motion sickness, Reactifargan is specifically differentiated by its topical route of administration. This distinction ensures its primary therapeutic focus remains localized to the skin surface, a feature recognized for immediate symptomatic relief.

Composition, Form, and General Purpose

The primary dosage form of Reactifargan is a cream or emulsion, specifically prepared for effective topical administration. The preparation is formulated as a single-active ingredient product, featuring Promethazine integrated into an emollient cream base or emulsion base that serves as the delivery vehicle. The general purpose of this topical preparation is to provide rapid symptomatic relief for acute, superficial skin irritations, such as localized discomfort following insect bites or minor instances of sunburn.

This relief is achieved through the compound’s antihistaminic action, which blocks the localized effects of histamine, and its intrinsic local anesthetic properties. Promethazine possesses H1 blocking and local anesthetic activity, supporting its utility as an agent for local antipruritic effects. This dual action helps concurrently reduce the sensations of intense itching and burning caused by irritants.

Regulatory References

  1. First-Generation H1 Antihistamines
  2. Phenothiazine Antipsychotics
  3. Topical Drug Administration
  4. Insect bites and stings
  5. Local Anesthetics

What side effects are possible with Reactifargan?

Possible Side Effects and Safety Information

The official safety profile for topical promethazine is primarily defined by local dermatological adverse reactions and the recognized potential for photosensitivity. Adverse reactions are categorized in regulatory documents based on frequency and system-organ class, with effects on the Skin and subcutaneous tissue disorders being the most commonly documented.

Localized skin irritation, such as a burning sensation or stinging upon application, is a common finding. Other officially listed reactions include allergic contact dermatitis, which is sometimes reported with a frequency of not known in post-marketing surveillance, and photosensitization, categorized as an uncommon risk tied to sun exposure during treatment.

Rare, but serious, documented adverse reactions include severe photosensitivity and the possibility of a systemic allergic reaction (sensitization) following percutaneous absorption. The risk of unwanted sedation or somnolence is also noted, particularly if the cream is applied over large or broken skin areas.

The regulatory labeling includes specific safety restrictions regarding the conditions of use. Application is restricted for areas of broken skin, infected wounds, eczema, or weeping dermatosis. Furthermore, official documents explicitly advise that sunlight and UV radiation exposure must be avoided while using the cream. A key population-specific constraint is the documented contraindication for use in children under 2 years of age due to heightened risk of systemic effects. The risk of contact sensitization is also associated with repeated or prolonged use of the preparation.

Overdose and Emergency Response

The official regulatory profile for Reactifargan overdose, based on excessive systemic exposure to Promethazine, documents a high risk for severe physiological and neurological manifestations. Urgent medical intervention is required due to the potential for life-threatening complications.

Documented Overdose Manifestations and Risks

Overdose may present with serious Central Nervous System (CNS) toxicity, which can result in profound drowsiness or coma in adults, or paradoxically, agitation and seizures in pediatric patients. Life-threatening outcomes officially documented include respiratory depression, apnea, severe cardiac dysrhythmias, and hypotension. Further signs of overexposure may include severe anticholinergic effects like mydriasis (dilated pupils) and hyperpyrexia (fever), with a documented risk of Neuroleptic Malignant Syndrome (NMS). Population-specific notes indicate that pediatric patients have an increased susceptibility to dystonias, while older adults may be more prone to severe confusion.

When Immediate Medical Help Is Required

Regulatory documents explicitly mandate that immediate emergency medical attention must be sought for any suspected overdose. This action is required due to the potential for rapid progression to life-threatening respiratory or cardiovascular instability. Management is strictly symptomatic and supportive, as no specific antidote is known. Protocols include continuous hospital monitoring, including ECG and vital signs monitoring, and may involve procedures such as gastric lavage or activated charcoal to limit systemic absorption.

Therapeutic Uses of Reactifargan

What Reactifargan Treats: Main Uses and Benefits

Reactifargan is used in situations involving certain distressing symptoms, applied across domains where additional symptomatic support is needed for acute, localized skin irritations. Topical promethazine is used for easing symptoms related to inflammatory or irritative states. The cream is commonly used to help with conditions presenting with acute episodes, such as intense localized itching (pruritus), the accompanying burning sensation, and the redness associated with minor allergic or environmental exposures. The preparation is relevant for managing symptom clusters that may become intense or disruptive, including those from insect bites, mild sunburn (solar erythema), and superficial allergic dermatitis flare-ups. The application provides support that helps ease the overall symptom burden, supporting patients during episodes of heightened discomfort.

“The preparation provides support that helps ease the overall symptom burden when symptoms are more noticeable.”

Quick Fact: Symptomatic Support for Acute Localized Discomfort
Symptom Domains: Intense Pruritus, Burning Sensation, Localized Irritation
Common Scenarios: Insect Bites, Minor Sunburn, Superficial Allergic Reactions
Patient Benefit: Helps improve day-to-day comfort during symptomatic periods

Eligibility and Restrictions for Use

Regulatory documents define eligibility for Reactifargan (Promethazine topical) based on age, physiological state, and pre-existing medical conditions.

Contraindicated Populations

The medicine is absolutely contraindicated for use in two primary groups, as mandated by the FDA and other regulators:

  • Pediatric patients less than two years of age (< 2 years old) due to the recognized potential for fatal respiratory depression.
  • Individuals with a known hypersensitivity to Promethazine, other phenothiazine derivatives, or any of the product’s excipients.

Age and Comorbidity Restrictions

Population Group Eligibility Status
Infants/Toddlers Contraindicated (Under 2 years of age)
Children Permitted with Caution (2 years of age and older)
Older Adults Use with Caution (Increased susceptibility to anticholinergic effects)

Eligibility is also restricted by pre-existing conditions. Caution is required for patients with impaired liver function, seizure disorders, narrow-angle glaucoma, or conditions causing bladder-neck obstruction.

Pregnancy and Application Site

Use during pregnancy is generally considered conditional, to be determined only if the benefits outweigh potential risks to the fetus. Use is not recommended in the two weeks prior to delivery. For all users, the cream must not be applied to broken skin or open wounds, and the treated area must be protected from sun exposure to prevent photosensitivity reactions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Reactifargan (Topical Promethazine) primarily notes that, due to the topical route of administration, the product is not likely to cause significant drug interactions when used at recommended doses.

However, regulatory labels include cautions based on the systemic profile of the active substance, Promethazine. These interactions are classified as pharmacodynamic effects and formal restrictions.


Documented Interaction Categories

Substance / Class Interaction Outcome Regulatory Classification
Monoamine Oxidase Inhibitors (MAOIs) Increased risk of extrapyramidal effects (Phenothiazine class caution) Formal Contraindication
CNS Depressants & Alcohol Additive effect leading to intensified sedative action Pharmacodynamic Interaction
Anticholinergic Agents Additive anticholinergic properties Pharmacodynamic Interaction
Epinephrine Should not be used to treat hypotension in overdose (risk of vasopressor reversal) Restriction

Procedural and Timing Restrictions

Official labeling mandates specific constraints unrelated to other medicinal products. Exposure to sun or ultraviolet (UV) light is a mandatory restriction and must be avoided during or shortly after treatment due to the potential for photosensitivity. Promethazine may also interfere with certain diagnostic procedures: it can cause false results in immunological pregnancy tests and interfere with the cutaneous histamine response, requiring the drug to be discontinued for at least 72 hours before conducting allergen skin tests.

Mechanism of Action

The pharmacological action of Promethazine, when applied locally, involves a dual mechanistic profile targeting two distinct signaling systems within the superficial skin layers. The mechanism is constrained to this region due to limited tissue penetration.

Antagonism of Histamine-Mediated Signaling

Promethazine functions as a competitive antagonist at the histamine H1 receptor, preventing the binding of endogenous histamine to these receptors on cutaneous nerve endings and vascular endothelial cells. This blockade interrupts the subsequent molecular signaling cascade, modulating the frequency of peripheral C-fiber discharge and attenuating histamine-induced vascular permeability.

Direct Inhibition of Peripheral Sensory Nerve Conduction

The molecule simultaneously acts as a reversible blocker of voltage-gated sodium ( Na^+) channels found on peripheral sensory neurons. By inhibiting the influx of sodium ions, the drug alters the sensory neuron membrane potential and prevents the generation and propagation of the electrical nerve impulse. This action interrupts the local nociceptive and pruritic signal transmission within the affected nerve fibers.

Dosage and Administration Information

Administration Guidelines: Reactifargan (Promethazine Topical Cream)

Reactifargan is a pharmaceutical preparation designated exclusively for topical application via the cutaneous route. Its official dosage form is a 2% cream. The administration protocol is strictly defined, emphasizing short-term use for acute symptomatic support.


Official Administration Protocol

Feature Official Instruction
Route of Administration Dermal (Cutaneous) application.
Dosing Schedule Application of a thin layer of the cream to the affected skin area.
Frequency Used on an as-needed basis, typically up to 2 to 3 times per day.
Course Duration Strictly short-term use; treatment must not exceed 3 or 4 days without medical consultation.
Preparation Requires no dilution or prior preparation before application.

Special Use Conditions and Constraints

The usage protocol for the cream includes mandatory conditions and procedural constraints defined in the prescribing information.

Procedural Constraints

The person applying the cream must wash hands thoroughly immediately after each use. Furthermore, the skin areas that have been treated must avoid exposure to the sun or ultraviolet A (UVA) radiation for the duration of the use period, as this is a requirement tied to the safe administration of the medication.

Population-Specific Rules

While usage is primarily defined for adults, the label provides specific instruction regarding certain populations. For instance, the cream must not be applied to the breasts during the period of lactation. Use in pediatric patients generally requires careful caution and often physician monitoring.

Recent Clinical Evidence

Reactifargan: Research Evidence Overview

Evidence Base for Acute Localized Skin Irritation

Topical promethazine was studied for conditions involving outcomes describing episodic or acute changes in localized pruritus (itching) and skin irritation, such as symptoms related to insect bites and minor sunburn. Early research examined the compound’s local pharmacological effects, with studies applied in research contexts involving fluctuating or unstable symptoms. Findings indicate that in the observed populations, the compound was associated with measured changes in the perceived levels of patient-reported outcomes describing perceived discomfort (itching and burning). The research landscape for this compound was evaluated by researchers as Moderate in its overall consistency, reflecting a reliance on both the established mechanism and evidence gathered over time.


Study Design and Measured Outcomes

The available research includes clinical bioavailability studies that monitored the compound’s rate of absorption through the skin. Other research explored the product’s local activity by objectively measuring how it affected histamine-induced skin reactivity in test subjects. Research highlights changes measured during the study period, including research highlighted changes in the objective wheal and flare response measurements. Bioavailability studies describe patterns suggesting that the compound may be absorbed into the systemic circulation in some of the observed populations. This body of evidence contributes to the broader evidence landscape by quantifying the extent of local absorption.


Evidence Gaps and Areas of Scientific Uncertainty

Long-term effects are not fully established, as the focus of the research is primarily on acute, self-limiting skin episodes. There is limited information for long-term outcomes or the durability of any effect beyond the immediate period of active irritation. The majority of dedicated topical studies was evaluated in healthy adult volunteers, meaning the results apply only to the populations studied. Data for certain groups, such as children or the elderly, remain insufficient for the topical cream. Comparative evidence is lacking for the specific topical cream formulation against many current standard-of-care treatments for localized pruritus.

Frequently Asked Questions (FAQ)

Common questions about Reactifargan (FAQ)


Q: How quickly can someone expect Reactifargan to start working?

A: Official documents describe the topical preparation as providing rapid symptomatic relief for acute, localized skin irritations. This reflects the compound’s dual action in quickly blocking localized histamine effects and sensory nerve signals at the application site. The description suggests the localized effects are intended to begin quickly after application.


Q: Can Reactifargan be taken with common pain relievers like ibuprofen or acetaminophen?

A: Regulatory information indicates that due to the topical route of application, Reactifargan is not likely to cause significant drug interactions when used at the recommended dose. This general guidance extends to most common over-the-counter pain relievers. Questions regarding specific drug combinations are best addressed by a healthcare professional.


Q: Does Reactifargan interact with birth control pills?

A: Official documents state that Reactifargan is not likely to cause significant drug interactions when used as directed, due to the topical route of administration. The label does not specifically mention interactions with hormonal contraceptives (birth control pills). This low-risk status is based on minimal expected systemic absorption.


Q: Can Reactifargan cause changes in mood or sleep patterns?

A: The official safety profile notes a risk of unwanted sedation or somnolence (sleepiness), particularly if the cream is applied to large or broken areas of skin. This effect relates to sleep patterns. However, information specifically detailing changes in mood is not addressed in the provided regulatory documents.


Q: Can Reactifargan affect driving or operating machinery?

A: Since the cream carries a noted risk of sedation or somnolence, especially with high absorption, official guidance generally advises users to be aware of their personal response to the product. In the event these side effects occur, caution is advised when performing activities that require full mental alertness, such as driving or operating heavy machinery.


Q: If I have a mild reaction to Reactifargan, does that mean I'm allergic?

A: Official safety information lists local effects like a burning sensation or stinging upon application as a common finding, and this is usually distinct from an actual allergic reaction. However, regulatory documents also note the possibility of a systemic allergic reaction or allergic contact dermatitis, which are more serious and may involve sensitization with repeated use.


Q: What is the main mechanism of action for Reactifargan, in simple terms?

A: Reactifargan works in two main ways to relieve itching and burning locally on the skin. First, it blocks the signals of a natural substance called histamine, which causes itching and swelling. Second, it gently interrupts the electrical signals in the local sensory nerves, which helps to stop the messages of pain and itching from being sent to the brain.


Q: Can Reactifargan be cut or crushed?

A: Reactifargan is a topical cream or emulsion intended only for application on the skin. Since it is not a pill or tablet, it cannot be cut, crushed, or chewed. The administration guidelines specify applying only a thin layer of the cream to the affected area.


Q: Is Reactifargan usually taken with food or on an empty stomach?

A: Reactifargan is strictly a topical cream that is applied to the skin, not an oral medicine that is swallowed. Therefore, instructions about taking it with food or on an empty stomach do not apply to this product.


Q: Can people with kidney or liver problems take Reactifargan?

A: Official eligibility guidelines specifically require caution for patients who have impaired liver function. The prescribing information does not provide specific instructions regarding the use of Reactifargan for individuals with kidney impairment.


Q: Are there different forms of Reactifargan (e.g., tablet, liquid)?

A: The branded product Reactifargan is officially defined as a topical preparation—a cream or emulsion—for application to the skin. While the active ingredient, Promethazine, is used in other forms (like tablets or syrups) for other medical uses, Reactifargan itself is specifically the topical cream.


Q: Does Reactifargan have any black box warnings?

A: Regulatory documents include a critical safety constraint for use in children under two years of age due to the risk of systemic effects like respiratory depression. While the official documents do not explicitly use the term 'Black Box Warning,' this constraint reflects a significant safety concern for this population.


Q: What happens if a dose of Reactifargan is missed?

A: Official information advises applying a missed dose as soon as remembered. However, if it is almost time for the next scheduled application, the missed dose should be skipped and the regular schedule continued. Compensating for a missed application by applying extra cream is generally not recommended.


Q: Are there any specific foods or drinks that should be avoided while taking Reactifargan?

A: Official guidance typically states that most users can continue a normal diet while using the cream. The primary caution relates to the systemic form of the active ingredient, Promethazine, which requires caution with alcohol due to the potential for intensified sedative effects.


Q: Is there a generic version of Reactifargan available?

A: Regulatory databases track the availability of generic medications. While Reactifargan is a specific brand name product, the active ingredient it contains, Promethazine, is widely available in generic form for various applications.


Q: Do you need a special kind of prescription to get Reactifargan?

A: The topical cream/emulsion form of Reactifargan requires a prescription. This is due to the safety profile and the fact that its active ingredient, Promethazine, is classified as a controlled substance in certain jurisdictions when in specific formulations. In some regions, this classification may require the prescription to be handled through electronic prescribing methods.


Q: Are there any known interactions between Reactifargan and supplements like St. John's Wort?

A: Official drug labels for the active ingredient, Promethazine, mention potential interactions with certain herbal supplements, including St. John's Wort. These interactions can increase side effects like drowsiness or confusion, though the risk is higher with systemic use. Disclosure of all supplement use to a healthcare provider is generally recommended.


Q: Why does Reactifargan require a prescription?

A: Reactifargan requires a prescription because of its specific safety profile, which includes documented risks like photosensitivity and the possibility of sedation. The drug also carries a serious contraindication for use in children under two years of age, which necessitates clinical oversight.


Q: What is the shelf life of Reactifargan?

A: The specific expiration date, or shelf life, of the sealed product is printed on the Reactifargan packaging and defined in the manufacturer’s official regulatory documents. Once the tube is opened, many topical creams have a shorter 'period after opening' (e.g., three months), after which they should be discarded.


Q: What should a user do if they suspect an interaction with Reactifargan?

A: Patient information leaflets from authoritative sources consistently direct users to seek guidance immediately if they suspect the product is interacting with another medicine or product. Suspected interactions or concerning effects typically require immediate contact with a healthcare professional or pharmacist.


Q: Are there any known interactions between Reactifargan and herbal teas?

A: Regulatory documents sometimes caution against the use of the active ingredient (Promethazine) with substances that may increase side effects like sedation or nervousness, including certain caffeine-containing drinks or herbal supplements. The disclosure of all herbal product use to a healthcare provider is typically advised.


Q: Does Reactifargan affect heart rate or blood pressure?

A: The active ingredient in Reactifargan, Promethazine, has been linked to cardiovascular side effects in its systemic form. These effects include potential changes in blood pressure (either low or high) and alterations in heart rate or rhythm. For individuals with pre-existing cardiovascular conditions, use of the product is generally advised with caution.


Q: Are the side effects of Reactifargan different depending on the dose?

A: Official safety information indicates that the risk of systemic side effects, such as sedation, may be greater if the cream is applied over a particularly large area of skin or skin that is broken. This is because these conditions can increase the amount of active ingredient absorbed into the body.


Q: What is Reactifargan's safety rating or classification from the FDA/EMA?

A: The active ingredient, Promethazine, is often assigned a US FDA Pregnancy Category C classification. This designation indicates that animal studies have shown potential risks, but potential benefits may still warrant the drug's use in pregnant women. Conditional eligibility for use in this population is managed under the guidance of a healthcare provider.

How should Reactifargan be stored and disposed of?

How to Store and Dispose of Reactifargan

The storage and disposal of Reactifargan cream must strictly adhere to the requirements specified in the official regulatory labeling to maintain the product's quality and ensure environmental safety.

Official Storage and Handling

Condition Requirement
Temperature Store at a temperature below 25 C (77 F).
Container Integrity The tube must be closed carefully after use.
Child Safety Keep the medicine out of the sight and reach of children.

Disposal Mandates

Unused or expired product must not be disposed of in household waste or wastewater. The official instruction requires that both the unused medicine and any related waste be disposed of in accordance with the local regulations in force.

This mandates using established pharmaceutical take-back programs or designated collection points rather than discarding the product in the drain or domestic refuse.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Reactifargan found in:

A-Z Index: